Primary Progressive Multiple Sclerosis -
-25% koodilla BOOKS
Toimitus 12-18 arkipäivässä
30 päivän palautusoikeus
"Why are there no effective treatments for my condition? Why do researchers exclude patients with primary progressive multiple sclerosis from enrolling in clinical trials? Please let me know if you hear of studies that I might be allowed to enter or treatments that I could try for my condition. " Thus, in recent years, the sad lament of the patient with primary progressive MS (PPMS). This variant, often in ... Täydellinen kuvaus
Saatat myös pitää
TOP
The Myth of Normal: Trauma, Illness, and Healing in a Toxic Culture
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
No Bad Parts: Healing Trauma and Restoring Wholeness with the Internal Family Systems Model
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
On Connection: 'Powerful' MATT HAIG
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
The Checklist Manifesto: How to Get Things Right
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
Harrison's Principles of Internal Medicine (Vol.1 & Vol.2)
Stephen Hauser, Joseph Loscalzo, Steven Holland, Dan Longo, J. Larry Jameson, Dennis Kasper, Carol Langford, Anthony Fauci
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
Oxford Handbook of Anaesthesia
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
Maybe You Should Talk to Someone: a therapist, her thearapist, and our lives revealed
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
How Not To Die: Discover the foods scientifically proven to prevent and reverse disease
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
Lifespan: Why We Age - and Why We Don't Have To
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
Vademecum Metabolicum: Diagnosis and Treatment of Inborn Errors of Metabolism Forword by William L. Nyhan, San Diego, USA
Johannes Zschocke, Georg F. Hoffmann
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
ROAR: How to Match Your Food and Fitness to Your Unique Female Physiology for Optimum Performance, Great Health, and a Strong, Lean Body for Life
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
Cellular and Molecular Immunology
Sarah Henrickson, Abul K. Abbas, Andrew H. Lichtman, Shiv Pillai
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
McGee's Evidence-Based Physical Diagnosis
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
Physics, Pharmacology and Physiology for Anaesthetists: Key Concepts for the FRCA
Matthew E. Cross, Emma V. E. Plunkett
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
Pocket Guide to Teaching for Clinical Instructors
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
Oxford Handbook of Critical Care
Andrew Webb, Mervyn Singer, Alice Carter
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
The Wills Eye Manual: Print + eBook with Multimedia: Office and Emergency Room Diagnosis and Treatment of Eye Disease
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
Vaccinated - dead: Histopathological findings following COVID-19 vaccination
-25% koodilla BOOKS
Toimittajalla varastossa
TOP
Steal Like an Artist: 10 Things Nobody Told You About Being Creative
-25% koodilla BOOKS
Toimittajalla varastossa
Kuvaus
"Why are there no effective treatments for my condition? Why do researchers exclude patients with primary progressive multiple sclerosis from enrolling in clinical trials? Please let me know if you hear of studies that I might be allowed to enter or treatments that I could try for my condition. " Thus, in recent years, the sad lament of the patient with primary progressive MS (PPMS). This variant, often in the guise of a chronic progressive myelopathy or, less commonly, progressive cerebellar or bulbar dysfunction, usually responds poorly to corticosteroids and rarely seems to benefit to a significant degree from intensive immunosuppressive treatments. In recent years, most randomized clin ical trials have excluded PPMS patients on two counts. Clinical worsening devel ops slowly in PPMS and may not be recognized during the course of a 2-or 3-year trial even in untreated control patients. This factor alone adds to the potential for a type 2 error or, at the very least, inflates the sample size and duration of the trial. In addition, there is mounting evidence that progressive axonal degeneration and neuronal loss (rather than active, recurrent inflammation) may be important components of the pathology in this form of the disease. Although contemporary trials are evaluating whether PPMS patients may benefit from treatment with the ~-interferons and glatiramer acetate, preliminary, uncontrolled clinical experi ence suggests that the results may not be dramatic.
Lisätietoja
| Julkaisija | Springer Milan |
|---|---|
| Series | Topics in Neuroscience |
| Julkaisuvuosi | 2012 |
| Kannen tyyppi | Pehmeäkantinen |
| EAN | 9788847022362 |